 |
      
|
|
|
|
|
|||||
|
|
November 3, 2005
Neurochem to present at CIBC World Markets Sixteenth Annual Healthcare Conference About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders.
The Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug, is a Fast Track product candidate
and is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was concluded in April 2005. The Company is in the process of
submitting a New Drug Application (NDA) for Fibrillex™ that the FDA has agreed to file and review.
3-amino-1-propanesulfonic acid (3APS; Alzhemed™), for the treatment of Alzheimer's disease, is currently in Phase
III clinical trials in both North America and Europe, and 3APS (Cerebril™), for the prevention of Hemorrhagic
Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at
the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which
Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due
to consolidation, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not
place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak
only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for further
risk factors that might affect the Company and its business.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
